Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2
The protein tyrosine phosphatase SHP2 is a key regulator of cell cycle control. Here the authors combine NMR measurements and X-ray crystallography and show that wild-type SHP2 dynamically exchanges between a closed inactive conformation and an open activated form and that the oncogenic E76K mutatio...
Saved in:
Main Authors: | Ricardo A. P. Pádua, Yizhi Sun, Ingrid Marko, Warintra Pitsawong, John B. Stiller, Renee Otten, Dorothee Kern |
---|---|
Format: | article |
Language: | EN |
Published: |
Nature Portfolio
2018
|
Subjects: | |
Online Access: | https://doaj.org/article/77cc04b8724e47ce9663728a803fea11 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition
by: Jonathan R. LaRochelle, et al.
Published: (2018) -
Discriminating between competing models for the allosteric regulation of oncogenic phosphatase SHP2 by characterizing its active state
by: Paolo Calligari, et al.
Published: (2021) -
Lymphocyte cell-cycle inhibition by HLA-G is mediated by phosphatase SHP-2 and acts on the mTOR pathway.
by: Farah Ketroussi, et al.
Published: (2011) -
Protein tyrosine phosphatase Shp2 deficiency in podocytes attenuates lipopolysaccharide-induced proteinuria
by: Ming-Fo Hsu, et al.
Published: (2017) -
PD-L2 suppresses T cell signaling via coinhibitory microcluster formation and SHP2 phosphatase recruitment
by: Tomohiro Takehara, et al.
Published: (2021)